These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 38158916

  • 1. [Hemostasis disorders in patients with systemic AL-amyloidosis].
    Rekhtina IG, Khyshova VA, Zozulya NI, Dvirnyk VN, Mendeleyeva LP.
    Ter Arkh; 2023 Nov 03; 95(9):746-750. PubMed ID: 38158916
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation.
    Pawlicki J, Cierpka L, Król R, Ziaja J.
    Transplant Proc; 2011 Oct 03; 43(8):3013-7. PubMed ID: 21996213
    [Abstract] [Full Text] [Related]

  • 3. [Thrombosis and disorders of hemostasis in nephrotic syndrome].
    Kanfer A.
    Nephrologie; 1992 Oct 03; 13(4):151-7. PubMed ID: 1407255
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of hemostasis disorders using the thrombodynamic test in patients with chronic glomerulonephritis with nephrotic syndrome].
    Berns AS, Sovetnikov EN, Chebotareva NV, Berns SA, Solonkina AD, Guliaev SV, Kraeva VV, Moiseev SV.
    Ter Arkh; 2022 Aug 04; 94(6):738-742. PubMed ID: 36286850
    [Abstract] [Full Text] [Related]

  • 5. Hemostatic dysfunction in paraproteinemias and amyloidosis.
    Zangari M, Elice F, Fink L, Tricot G.
    Semin Thromb Hemost; 2007 Jun 04; 33(4):339-49. PubMed ID: 17525891
    [Abstract] [Full Text] [Related]

  • 6. Hemostatic abnormalities in nephrotic syndrome.
    Abdullah R.
    Vet Clin North Am Small Anim Pract; 1988 Jan 04; 18(1):105-13. PubMed ID: 3282374
    [Abstract] [Full Text] [Related]

  • 7. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis.
    Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, Merlini G.
    Amyloid; 1999 Dec 04; 6(4):273-7. PubMed ID: 10611948
    [Abstract] [Full Text] [Related]

  • 8. Thromboelastometry as a supplementary tool for evaluation of hemostasis in severe sepsis and septic shock.
    Andersen MG, Hvas CL, Tønnesen E, Hvas AM.
    Acta Anaesthesiol Scand; 2014 May 04; 58(5):525-33. PubMed ID: 24580049
    [Abstract] [Full Text] [Related]

  • 9. Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality.
    Gastineau DA, Gertz MA, Daniels TM, Kyle RA, Bowie EJ.
    Blood; 1991 Jun 15; 77(12):2637-40. PubMed ID: 1904284
    [Abstract] [Full Text] [Related]

  • 10. The hypercoagulable states.
    Schafer AI.
    Ann Intern Med; 1985 Jun 15; 102(6):814-28. PubMed ID: 3158262
    [Abstract] [Full Text] [Related]

  • 11. Clotting alterations in primary systemic amyloidosis.
    Gamba G, Montani N, Anesi E, Palladini G, Capezzera M, Soldavini E, Merlini G.
    Haematologica; 2000 Mar 15; 85(3):289-92. PubMed ID: 10702818
    [Abstract] [Full Text] [Related]

  • 12. [Clinical value of the study of hemostasis in nephrology].
    Mukhin NA, Poliantseva LR, Kozlovskaia LV, Kozlovskaia NL, Charyev BM.
    Ter Arkh; 1988 Mar 15; 60(6):7-13. PubMed ID: 3206376
    [Abstract] [Full Text] [Related]

  • 13. Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
    Quitt M, Aghai E, David M, Kohan R, Ben Ari Y, Froom P.
    Scand J Haematol; 1985 Aug 15; 35(2):155-7. PubMed ID: 3876596
    [Abstract] [Full Text] [Related]

  • 14. Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.
    Warrillow S, Fisher C, Tibballs H, Bailey M, McArthur C, Lawson-Smith P, Prasad B, Anstey M, Venkatesh B, Dashwood G, Walsham J, Holt A, Wiersema U, Gattas D, Zoeller M, Garcia Alvarez M, Bellomo R.
    J Gastroenterol Hepatol; 2020 May 15; 35(5):846-854. PubMed ID: 31689724
    [Abstract] [Full Text] [Related]

  • 15. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.
    Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M.
    Br J Haematol; 2000 Aug 15; 110(2):454-60. PubMed ID: 10971408
    [Abstract] [Full Text] [Related]

  • 16. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients.
    Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D.
    Semin Nephrol; 2004 Sep 15; 24(5):495-501. PubMed ID: 15490419
    [Abstract] [Full Text] [Related]

  • 17. Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers.
    Walenga JM, Hoppensteadt D, Fareed J, Pifarré R.
    Ann Thorac Surg; 1992 May 15; 53(5):844-50. PubMed ID: 1570981
    [Abstract] [Full Text] [Related]

  • 18. Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
    Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE.
    J Am Soc Nephrol; 2015 Dec 15; 26(12):3009-19. PubMed ID: 25855774
    [Abstract] [Full Text] [Related]

  • 19. Thrombotic and bleeding complications in patients with AL amyloidosis.
    Fotiou D, Theodorakakou F, Spiliopoulou S, Gavriatopoulou M, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Roussou M, Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA, Kastritis E.
    Br J Haematol; 2024 May 15; 204(5):1816-1824. PubMed ID: 38321638
    [Abstract] [Full Text] [Related]

  • 20. [THROMBOTIC COMPLICATIONS AND LATENT HYPERCOAGULATION IN PATIENTS WITH BETA-THALASSEMIA].
    Alieva N, Kerimov A, Safarova P, Mamedsalahova P.
    Georgian Med News; 2022 Mar 15; (324):139-145. PubMed ID: 35417875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.